Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia

Dartmouth-Hitchcock Medical Center1 site in 1 countryMay 2010

ConditionsChronic Lymphocytic Leukemia

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Chronic Lymphocytic Leukemia
Sponsor: Dartmouth-Hitchcock Medical Center
Locations: 1
Primary Endpoint: To identify the genes that are differentially expressed at the polysomal RNA and protein levels in human patient CLL cells (compared to normal donor lymphocytes) using high-throughput microarray approaches.
Status: Withdrawn
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to collect a blood sample from patients with Chronic Lymphocytic Leukemia (CLL) and from volunteers without CLL.

Detailed Description

The blood sample will be used in the laboratory to perform focused studies on Chronic Lymphocytic Leukemia (CLL).

Registry

clinicaltrials.gov

Start Date

May 2010

End Date

February 2011

Last Updated

8 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Dartmouth-Hitchcock Medical Center

Responsible Party

Principal Investigator

Christopher H. Lowrey

Professor of Medicine and of Pharmacology and Toxicology

Dartmouth-Hitchcock Medical Center

Eligibility Criteria

Inclusion Criteria

•Patients undergoing routine blood draws as part of their ongoing follow-up care for CLL at the Norris Cotton Cancer Center of DHMC.
•Normal donors who have no history of active or prior hematologic malignancy.

Exclusion Criteria

•Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for their CLL, other hematologic malignancy or other disease process within the past 2 months are excluded. Use of intravenous immunoglobulin (IVIg) is not a reason for exclusion.
•Normal donors who have a history of steroid use, immunosuppression therapy or autoimmune disease are excluded.

Outcomes

Primary Outcomes

To identify the genes that are differentially expressed at the polysomal RNA and protein levels in human patient CLL cells (compared to normal donor lymphocytes) using high-throughput microarray approaches.

Time Frame: 2 Years

Secondary Outcomes

To determine whether the novel candidate genes from Specific Aim 1 have potential roles in CLL. (Note: Specific Aim 2 does not involve human subjects research).(2 Years)